Ruoning Wang
Biochemistry, Genetics and Molecular Biology · The Ohio State University
Publications
155
Citations
11,567
Est. group size
~7
Recurring co-author estimate
Active years
25
Publishing since 2002
Ruoning Wang's research focuses on how cancer cells rewire their metabolism and interact with the immune system, particularly in cancers driven by the MYC gene such as neuroblastoma and liver cancer. Recent work explores how metabolic changes in tumors and immune cells influence cancer growth and treatment response, including approaches like CAR-T cell therapy, immune-based nanoparticle delivery, and drugs that alter cancer cell behavior. The lab combines mouse models, cell biology, and genomic/epigenetic analysis to study tumor development and to design new immunotherapy strategies.
Publication output has grown substantially over the past decade, rising from about 6 papers per year in 2017-2019 to around 17-20 per year in 2024-2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Supplementary Table S5 from Conditional Activation of c-MYC in Distinct Catecholaminergic Cells Drives Development of Neuroblastoma or Somatostatinoma
2026
- Supplementary Table S1 from Conditional Activation of c-MYC in Distinct Catecholaminergic Cells Drives Development of Neuroblastoma or Somatostatinoma
2026
- Supplementary Table S4 from Conditional Activation of c-MYC in Distinct Catecholaminergic Cells Drives Development of Neuroblastoma or Somatostatinoma
2026
- Supplementary Table S3 from Conditional Activation of c-MYC in Distinct Catecholaminergic Cells Drives Development of Neuroblastoma or Somatostatinoma
2026
- Homologous magnetic targeted immune vesicles for amplifying immunotherapy via ferroptosis activation augmented photodynamic therapy against glioblastoma
Journal of Controlled Release · 2025
- RBM39 degrader invigorates innate immunity to eradicate neuroblastoma despite cancer cell plasticity
Nature Communications · 2025
- Metabolic Dialogue Shapes Immune Response in the Tumor Microenvironment
European Journal of Immunology · 2025
- The context-dependent epigenetic and organogenesis programs determine 3D vs. 2D cellular fitness of MYC-driven murine liver cancer cells
eLife · 2025
- Recharging aged-CAR with NAD+ to boost immunotherapy
Trends in cancer · 2025
- The context-dependent epigenetic and organogenesis programs determine 3D vs. 2D cellular fitness of MYC-driven murine liver cancer cells
eLife · 2025
- The context-dependent epigenetic and organogenesis programs determine 3D vs. 2D cellular fitness of MYC-driven murine liver cancer cells
Research Square · 2025
- The context-dependent epigenetic and organogenesis programs determine 3D vs. 2D cellular fitness of MYC-driven murine liver cancer cells
eLife · 2025
- The context-dependent epigenetic and organogenesis programs determine 3D vs. 2D cellular fitness of MYC-driven murine liver cancer cells
eLife · 2025
- Supplementary Table S5 from Conditional Activation of c-MYC in Distinct Catecholaminergic Cells Drives Development of Neuroblastoma or Somatostatinoma
2025
- Supplementary Table S1 from Conditional Activation of c-MYC in Distinct Catecholaminergic Cells Drives Development of Neuroblastoma or Somatostatinoma
2025
- bioRxiv (Cold Spring Harbor Laboratory)×15
- eLife×8
- Nature Metabolism×5
- Research Square×5
- Science Advances×4
- John Wang
Biochemistry, Genetics and Molecular Biology · Indiana University
- Charles E. Dann
Biochemistry, Genetics and Molecular Biology · Indiana University
- Aneesha Dasgupta
Biochemistry, Genetics and Molecular Biology · Indiana University
- Anjali Gupta
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Chaylen Andolino
Biochemistry, Genetics and Molecular Biology · Purdue University West Lafayette
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile